Daurinol, a catalytic inhibitor of topoisomerase IIα, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase

Kang,Kyungsu; Nho,Chu Won; Kim,Nam Doo; Song,Dae-Geun; Park,Young Gyun; Kim,Minkyun; Pan,Cheol-Ho; Shin,Dongyun; Oh,Seung Hyun; Oh,Ho-Suk

doi:10.3892/ijo.2014.2442

Daurinol, a catalytic inhibitor of topoisomerase IIα, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase

Authors:
- Kyungsu Kang
- Chu Won Nho
- Nam Doo Kim
- Dae-Geun Song
- Young Gyun Park
- Minkyun Kim
- Cheol-Ho Pan
- Dongyun Shin
- Seung Hyun Oh
- Ho-Suk Oh
View Affiliations

Affiliations: Functional Food Center, Korea Institute of Science and Technology, Gangneung, Republic of Korea, New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, Republic of Korea, Department of Agricultural Biotechnology, Seoul National University, Seoul, Republic of Korea, College of Pharmacy, Gachon University, Incheon, Republic of Korea, Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea
Published online on: May 16, 2014 https://doi.org/10.3892/ijo.2014.2442
Pages: 558-566

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Daurinol, a lignan from the ethnopharmacological plant Haplophyllum dauricum, was recently reported to be a novel topoisomerase II inhibitor and an alternative to the clinical anticancer agent etoposide based on a colorectal cancer model. In the present study, we elucidated the detailed biochemical mechanism underlying the inhibition of human topoisomerase IIα by daurinol based on a molecular docking study and in vitro biochemical experiments. The computational simulation predicted that daurinol binds to the ATP-binding pocket of topoisomerase IIα. In a biochemical assay, daurinol (10-100 µM) inhibited the catalytic activity of topoisomerase IIα in an ATP concentration-dependent manner and suppressed the ATP hydrolysis activity of the enzyme. However, daurinol did not inhibit topoisomerase I activity, most likely because topoisomerase I does not contain an ATP-binding domain. We also evaluated the anti-proliferative activity of daurinol in ovarian, small cell lung and testicular cancer cells, common target cancers treated with etoposide. Daurinol potently inhibited SNU-840 human ovarian cancer cell proliferation through cell cycle arrest in S phase, while etoposide induced G2/M phase arrest. Daurinol induced the increased expression of cyclin E, cyclin A and E2F-1, which are important proteins regulating S phase initiation and progression. Daurinol did not induce abnormal cell and nuclear enlargement in SNU-840 cells, in contrast to etoposide. Based on these data, we suggest that daurinol is a potential anticancer drug candidate for the treatment of human ovarian cancer with few side effects.

View Figures

View References

1	Bailly C: Contemporary challenges in the design of topoisomerase II inhibitors for cancer chemotherapy. Chem Rev. 112:3611–3640. 2012. View Article : Google Scholar : PubMed/NCBI
2	Pogorelcnik B, Perdih A and Solmajer T: Recent advances in the development of catalytic inhibitors of human DNA topo-isomerase IIα as novel anticancer agents. Curr Med Chem. 20:694–709. 2013.PubMed/NCBI
3	Ezoe S: Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health. 9:2444–2453. 2012. View Article : Google Scholar : PubMed/NCBI
4	Chen W, Qiu J and Shen YM: Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs. Drug Discov Ther. 6:230–237. 2012.
5	Kang K, Oh SH, Yun JH, et al: A novel topoisomerase inhibitor, daurinol, suppresses growth of HCT116 cells with low hematological toxicity compared to etoposide. Neoplasia. 13:1043–1057. 2011.PubMed/NCBI
6	Batsuren D, Batirov EK, Malikov VM, Zemlyanskii VN and Yagudaev MR: Arylnaphthalene lignans of Haplophyllum dauricum. The structure of daurinol. Chem Nat Compd. 17:223–225. 1981.
7	Graham JG, Quinn ML, Fabricant DS and Farnsworth NR: Plants used against cancer - an extension of the work of Jonathan Hartwell. J Ethnopharmacol. 73:347–377. 2000. View Article : Google Scholar : PubMed/NCBI
8	Hande KR: Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer. 34:1514–1521. 1998. View Article : Google Scholar : PubMed/NCBI
9	Park JE, Lee J, Seo SY and Shin D: Regioselective route for arylnaphthalene lactones: convenient synthesis of taiwanin C, justicidin E, and daurinol. Tetrahedron Lett. 55:818–820. 2014. View Article : Google Scholar
10	Lanzetta PA, Alvarez LJ, Reinach PS and Candia OA: An improved assay for nanomole amounts of inorganic phosphate. Anal Biochem. 100:95–97. 1979. View Article : Google Scholar : PubMed/NCBI
11	Kang K, Jin YM, Jeon H, et al: The three proline residues (P25, P242, and P434) of Agrobacterium CP4 5-enolpyruvylshikimate-3-phosphate synthase are crucial for the enzyme activity. Plant Biotechnol Rep. 4:329–334. 2010. View Article : Google Scholar
12	Jun KY, Lee EY, Jung MJ, et al: Synthesis, biological evaluation, and molecular docking study of 3-(3′-heteroatom substituted-2′-hydroxy-1′-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor. Eur J Med Chem. 46:1964–1971. 2011.
13	Robinson MJ, Corbett AH and Osheroff N: Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II. Biochemistry. 32:3638–3643. 1993. View Article : Google Scholar : PubMed/NCBI
14	Kang K, Lee HJ, Kim CY, et al: The chemopreventive effects of Saussurea salicifolia through induction of apoptosis and phase II detoxification enzyme. Biol Pharm Bull. 30:2352–2359. 2007.
15	Kang K, Lee HJ, Yoo JH, et al: Cell and nuclear enlargement of SW480 cells induced by a plant lignan, arctigenin: evaluation of cellular DNA content using fluorescence microscopy and flow cytometry. DNA Cell Biol. 30:623–629. 2011. View Article : Google Scholar : PubMed/NCBI
16	Kang K, Lee SB, Yoo JH and Nho CW: Flow cytometric fluorescence pulse width analysis of etoposide-induced nuclear enlargement in HCT116 cells. Biotechnol Lett. 32:1045–1052. 2010. View Article : Google Scholar : PubMed/NCBI
17	Roca J: The mechanisms of DNA topoisomerases. Trends Biochem Sci. 20:156–160. 1995. View Article : Google Scholar
18	Larsen AK, Escargueil AE and Skladanowski A: Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther. 99:167–181. 2003. View Article : Google Scholar : PubMed/NCBI
19	Eastman A: Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem. 91:223–231. 2004. View Article : Google Scholar : PubMed/NCBI
20	Masai H, Matsumoto S, You Z, Yoshizawa-Sugata N and Oda M: Eukaryotic chromosome DNA replication: where, when, and how? Annu Rev Biochem. 79:89–130. 2010. View Article : Google Scholar : PubMed/NCBI
21	DeGregori J, Kowalik T and Nevins JR: Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol. 15:4215–4224. 1995.PubMed/NCBI
22	Gui M, Shi DK, Huang M, et al: D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase IIα. Invest New Drugs. 29:800–810. 2011.PubMed/NCBI
23	Schmeisser S, Schmeisser K, Weimer S, et al: Mitochondrial hormesis links low-dose arsenite exposure to lifespan extension. Aging cell. 12:508–517. 2013. View Article : Google Scholar : PubMed/NCBI
24	Dengg M and van Meel JC: Caenorhabditis elegans as model system for rapid toxicity assessment of pharmaceutical compounds. J Pharmacol Toxicol Methods. 50:209–214. 2004. View Article : Google Scholar
25	van den Heuvel S and Kipreos ET: C. elegans cell cycle analysis. Methods Cell Biol. 107:265–294. 2012.